Adverse effects of chronic low level lead exposure on kidney function--a risk group study in children

L M Fels1, M Wünsch, J Baranowski

  • 1Division of Nephrology, Medical School Hannover, Germany.

Insights

Children exposed to lead (Pb) show kidney damage even at low levels, confirming they are a special risk group. This study used urinary markers to assess kidney function in children with blood lead levels (b-Pb) just above the adverse effect threshold.

Area of Science:

  • Environmental Health
  • Pediatric Nephrology
  • Toxicology

Background:

  • Children are a vulnerable group for lead (Pb) toxicity, with potential neurodevelopmental deficits.
  • The current lowest adverse effect level for blood lead (b-Pb) is 100 microg/l.
  • Kidney damage from Pb exposure in children requires further nephrological assessment.

Purpose of the Study:

  • To compare kidney function in children with b-Pb just above the threshold versus unexposed children.
  • To evaluate the justification of the current Pb exposure threshold from a nephrological perspective.
  • To determine if children are a particularly vulnerable risk group for Pb-induced kidney damage.

Main Methods:

  • A cross-sectional study involving 112 children (50 controls, 62 exposed).
  • Measurement of 29 urinary or serum markers of kidney function and integrity.
  • Comparison of children from unexposed and Pb-contaminated areas with varying b-Pb levels.

Main Results:

  • Exposed children had significantly higher b-Pb levels (133+/-62 microg/l) than controls (39+/-13 microg/l).
  • Increased excretion of specific urinary markers (prostaglandins, thromboxane B2, epidermal growth factor, beta2-microglobulin, Clara cell protein) in exposed children.
  • A correlation was observed between b-Pb levels and abnormal marker values.

Conclusions:

  • Chronic low-level lead exposure causes detectable nephron-specific effects in children.
  • The observed kidney effects in children occur at lower b-Pb levels than in adults.
  • The current Pb exposure threshold is supported nephrologically, and children are confirmed as a special risk group.
Abstract

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...